Patient Access & Affordability
  • About
    • Mission
    • Who We Are
    • Advisory Board
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
      • Featured Work
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page

Fast Facts

ICER’s 1/31/2020 Final Release of the 2020 Value Assessment Framework

Fast Facts: ICER’s 2020 Value Assessment Framework

ICER’s 1/9/2020 Final Evidence Report on JAK Inhibitors for Rheumatoid Arthritis

Fast Facts: JAK Inhibitors for Rheumatoid Arthritis

ICER’s 12/9/2019 Final Evidence Report on Oral Semaglutide for Type 2 Diabetes Mellitus

Fast Facts: Oral Semaglutide for Type 2 Diabetes Mellitus

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS